Trials / Completed
CompletedNCT04185051
A Study to Investigate the Effect of JNJ-67953964 on Gastric Mucosal Integrity in Healthy Male and Female Participants
A Double-blind, Randomized, Placebo Controlled, 4-week Study to Investigate the Effect of JNJ-67953964 on Gastric Mucosal Integrity in Healthy Male and Female Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of the study is to investigate the upper gastro-intestinal (GI)-related safety and tolerability in healthy participants by gastroscopy and gastric biopsies after treatment with 25 milligram (mg) JNJ-67953964 once daily (QD) over 4 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-67953964 | Participants will receive JNJ-67953964 as oral capsules. |
| DRUG | Placebo | Participants will receive matching placebo oral capsules. |
Timeline
- Start date
- 2019-12-17
- Primary completion
- 2021-04-21
- Completion
- 2021-05-05
- First posted
- 2019-12-04
- Last updated
- 2025-04-27
Locations
1 site across 1 country: Belgium
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04185051. Inclusion in this directory is not an endorsement.